Renin Profiling in Selection of Initial Antihypertensive Drug

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

185 participants

Study Classification

INTERVENTIONAL

Study Start Date

2005-12-31

Study Completion Date

2011-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this research study is to determine whether a simple blood test measuring a hormone called renin can better determine which first drug would be most effective in controlling blood pressure, in comparison with the more traditional approach recommended by JNC7 (Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Trial to Compare the Effects of Either Telmisartan (40-80 mg PO Once Daily) or Ramipril (5-10 mg PO Once Daily) on Renal Endothelial Dysfunction in Hypertensive Patients With Type 2 Diabetes

NCT00240422

Diabetes Mellitus, Type 2 Hypertension

COMPLETED PHASE4

Survey to Assess Why People Are Not Responding to Treatment in Hypertension

NCT01071681

Arterial Hypertension

COMPLETED

Hypertensive Ambulatory Trial to Compare the Efficacy of HCTZ and Lisinopril

NCT01258764

Hypertension, Grade 1 Hypertension Treatment N of 1 Study Design +1 more

COMPLETED NA

Multi-Omics to Predict the Blood Pressure Response to Antihypertensives

NCT05917275

Primary Hypertension

RECRUITING PHASE4

Blood Pressure Lowering Ability and Safety of an Olmesartan and Amlodipine Based Treatment Regimen in Patients With Stage I and Stage II Hypertension

NCT00527514

Hypertension

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Hypothesis: That antihypertensive drug selection guided by activity of the renin angiotensin system will be superior to the strategy advocated in JNC 7 in achieving blood pressure control on monotherapy.

Background: the National Heart, Lung, and Blood Institute, through the Joint National Committee on the Detection, Treatment and Control of Hypertension (JNC 7) has recommended that most hypertensive patients begin therapy with a diuretic and sequentially add other classes of drugs until blood pressure is controlled. This approach appears to assume homogeneity in the mechanism by which BP is controlled in different patients. When this standardized strategy has been rigidly applied in Clinical Trials, a majority of patients generally require 2 or more agents to achieve blood pressure control.

The pioneering work of Laragh, Sealey and their colleagues, widely confirmed by others, suggests instead that heterogeneity, in fact, characterizes patterns of blood pressure control in populations. This heterogeneity can be exposed through assessment of the activity of the renin angiotensin system (RAS). Specifically, volume and vasoconstriction determine blood pressure control. Patients in whom volume predominates have suppressed RAS, and, conversely, those in whom vasoconstriction predominates will have an activated RAS. This can be simply and accurately determined by estimation of plasma renin activity (PRA).

It has been demonstrated that volume and vasoconstriction dependent hypertensive patients respond best to different drugs. By exploitation of the RAS it is possible to provide rational therapy to each patients according to the mechanism by which blood pressure is controlled. The result is that appropriate therapy can be both more effective and more efficient. A specific system the Laragh Method has been designed to translate this physiologically based paradigm into a practical scheme or patient management.

The purpose of this trial is to determine whether the Laragh Method will lead to better and more efficient blood pressure control in a general population of hypertensive patients than does the existing treatment strategy. The measure by which this hypothesis will be tested is percentage of hypertensive patients achieving blood pressure control on monotherapy.

The significance of this trial is enormous for both individuals and society. Some 50 million Americans have hypertension and more than 25 million are currently in treatment. If the Laragh Method leads to more parsimonious and effective care, it will mean literally millions of individual patients will be spared the burden of unnecessary polypharmacy. Moreover, the strain on health care costs associated with antihypertensive therapy will be redu

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hypertension

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

HCTZ , ARB

Patients randomized to the Experimental Arm have initial drug choice determined by Plasma Renin Activity level. Low renin subjects are assigned to the diuretic hydrochlorothothiazide. Those with PRA \>.65 ng/hr are assigned to the angiotensin receptor blocker, olmesartan.

Group Type EXPERIMENTAL

olmesartan, hydrochlorothiazide, amlodipine

Intervention Type DRUG

hydrochlorothiazide (HCTZ) 25mg OD, increased to 50 mg OD at 3 weeks. Olmesartan 20 mg OD, to be increased to 40 mg at 3 weeks. Amlodipine 5 mg, may be added at 6 weeks, if BP \>140 mmHg

hydrochlorothiazide (HCTZ) or olmesartan

Intervention Type DRUG

HCTZ 25 mg, increasing to 50 mg at 3-4 weeks or Olmesartan 20 mg, increasing to 40 mg at 3-4 weeks. If blood pressure \>140/90 mmHg at 6 weeks, amlodipine 5 mg may be added

Conventional antihypertensive therapy

All patients randomized to Active Comparator Arm received hydrochlorothiazide 25 mg, which is increased to 50 mg at 3-4 weeks. At 6 weeks, olmesartan may be added if BP \> 140 mmHg

Group Type ACTIVE_COMPARATOR

olmesartan, hydrochlorothiazide, amlodipine

Intervention Type DRUG

hydrochlorothiazide (HCTZ) 25mg OD, increased to 50 mg OD at 3 weeks. Olmesartan 20 mg OD, to be increased to 40 mg at 3 weeks. Amlodipine 5 mg, may be added at 6 weeks, if BP \>140 mmHg

hydrochlorothiazide (HCTZ) or olmesartan

Intervention Type DRUG

HCTZ 25 mg, increasing to 50 mg at 3-4 weeks or Olmesartan 20 mg, increasing to 40 mg at 3-4 weeks. If blood pressure \>140/90 mmHg at 6 weeks, amlodipine 5 mg may be added

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

olmesartan, hydrochlorothiazide, amlodipine

hydrochlorothiazide (HCTZ) 25mg OD, increased to 50 mg OD at 3 weeks. Olmesartan 20 mg OD, to be increased to 40 mg at 3 weeks. Amlodipine 5 mg, may be added at 6 weeks, if BP \>140 mmHg

Intervention Type DRUG

hydrochlorothiazide (HCTZ) or olmesartan

HCTZ 25 mg, increasing to 50 mg at 3-4 weeks or Olmesartan 20 mg, increasing to 40 mg at 3-4 weeks. If blood pressure \>140/90 mmHg at 6 weeks, amlodipine 5 mg may be added

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Renin guided selection of treatment Standard Therapy

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Males and females, 40 to 85 years of age
* Sustained systolic blood pressure between 140-180 mm Hg
* Free of antihypertensive therapy at randomization for at least 4 weeks

Exclusion Criteria

* Ages \<40, or \>85 years
* Systolic blood pressure \>180 mm Hg
* Blood pressure \>180/105 mm Hg during the washout period
* Require antihypertensive agents for non-blood pressure indications
* Taking clonidine
* On a beta-blocker drug and have known or suspected coronary artery disease
* Documented history of a heart attack, new onset of chest pain, or a coronary revascularization procedure within the past year, congestive heart failure
* Serious intercurrent illness
* An active ulcer
* Have certain abnormal laboratory tests (elevated serum creatinine \>1.5 mg/dl, transaminase \> 2 times upper limit of normal or active liver disease),
* Hypersensitivity, allergy or have an intolerance to angiotensin II receptor blockers (olmesartan), hydrochlorothiazide or amlodipine
* Mentally or legally unable to participate
* Have or are currently abusing alcohol, have abused drugs within the past 2 years
* Have been in another drug study in the past month.

Minimum Eligible Age

40 Years

Maximum Eligible Age

85 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Michael H. Alderman

Professor of Epidemiology and Population Health

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Michael H Alderman, M.D.

Role: PRINCIPAL_INVESTIGATOR

Albert Einstein College of Medicine

Locations

Explore where the study is taking place and check the recruitment status at each participating site.